Journal of Environmental Pathology, Toxicology and Oncology

ISSN for PRINT: 0731-8898

For Online Access

Best Paper Award Selection - Editorial Board Site

2002, Volume21

Issue 1

98 pages

Issue price - $160.00

Ranbir C. Sobti
Department of Biotechnology, Panjab University, Chandigarh, India

Kamana Parashar
Department of Biotechnology, Panjab University, Chandigarh, India

Raminder Kaur
Department of Biotechnology, Panjab University, Chandigarh, India

Neena Capalash
Department of Biotechnology, Panjab University, Chandigarh, India

Human papillomavirus (HPV) was detected in 85% and 63.6% of patients with invasive cervical cancer and minor cervical abnormalities, respectively. HPV-16 was the dominant type in both groups of women. Because of the high oncogenic potential of HPV-16 and the greater chance of its persistence, a follow-up of cases with minor cervical abnormalities harboring HPV-16 is warranted in order to observe the progression of the lesion. As many as 61.5% of the cases with invasive cervical cancer were found to have higher levels of serum p53 protein than did healthy controls. None of the patients had antibodies against the overexpressed p53. This suggests that, even if mutated, the p53 protein may not be immuno-genic in all cases. An inverse relationship between the presence of HPV and the alteration in p53 expression was observed in 71.43% of the cases. This could mean the loss of p53 function as a result of either HPV-E6-mediated degradation or mutation in the p53 gene.

Download article, 7 pages

Article price - $35.00

<< Previous article   Next article >>